A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs REGN-7508 (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ROXI-APEX
Most Recent Events
- 17 Jun 2025 New source identified and integrated (ClinicalTrial.gov: NCT07015905)
- 11 Jun 2025 Status changed from planning to not yet recruiting.
- 24 Dec 2024 New trial record